<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6506A2B9-0242-4F99-BB83-6BE3FE99DE90"><gtr:id>6506A2B9-0242-4F99-BB83-6BE3FE99DE90</gtr:id><gtr:firstName>Taane</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/88F11911-A359-49C4-81A2-5043BCB61EDB"><gtr:id>88F11911-A359-49C4-81A2-5043BCB61EDB</gtr:id><gtr:firstName>Judith</gtr:firstName><gtr:surname>Glynn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN010469%2F1"><gtr:id>56A1509B-C370-4098-ACD7-30759CB34C14</gtr:id><gtr:title>Understanding the transmission of tuberculosis using Mycobacterium tuberculosis sequence data</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N010469/1</gtr:grantReference><gtr:abstractText>Tuberculosis is an infectious disease that causes a high public health burden. The World Health Organisation estimates that there are nine million new cases and nearly two million deaths each year. Establishing who transmits to whom and where is fundamental to disease control. By comparing the genetic profiles of tuberculosis-causing bacteria within large population-based studies we can identify likely transmissions based on the similarity of the strains. Our work will focus initially on a district of Malawi where tuberculosis disease prevalence has been high, and data and tuberculosis samples from nearly 2500 patients have been collected over twenty years. The inferred genetic profiles will use a higher proportion of the genome than used previously, allowing more accurate reconstructions of transmission chains. Factors influencing transmissibility will then be assessed directly by looking at the patterns of data within each transmission chain. These factors may be genetic variations within the bacteria themselves, or differences in the human hosts, including age, sex, HIV infection and treatment, and contact patterns. We will attempt to confirm any insights into these factors using data collected and generated from other populations. Ultimately, an improved understanding of the genetic and other processes underlying transmissibility could lead to the development of improved control measures. These could include novel drug or vaccine targets, or identification of geographical or socially determined hotspots of transmission.</gtr:abstractText><gtr:technicalSummary>Tuberculosis, caused by Mycobacterium tuberculosis, is an important global public health issue. Understanding the factors underlying transmission is essential for disease control, but surprisingly little is known about the role of pathogen genomic variation, where most infections occur, the importance of host factors, or who transmits to whom. M. tuberculosis can be grouped into seven lineages or phylogenetic clades, and further into sub-lineages, which may vary in propensity to transmit and cause disease. By sequencing M. tuberculosis in a population-based setting it is possible to construct transmission chains using phylogenetic-based algorithms: strains with near identical genomes are most likely to be due to a transmission event, and will appear on the same branch of the phylogenetic tree. However, there are few large population-based studies in high tuberculosis prevalence areas that can apply long-term large-scale whole genome sequencing. Here we focus on the Karonga study in northern Malawi where substantial epidemiological data have been collected and ~2500 sequenced samples are available spanning a 20-year period. Sequencing studies to date have been limited to single nucleotide polymorphisms and have ignored insertions and deletions and highly variable regions such as the pe/ppe gene families. By including all these variations and considering all the tuberculosis cases in the Karongan population, it will be possible to build a probabilistic model of transmissions, and hence assess effects of pathogen variation and host factors (age, sex, HIV status, contact patterns, proximity) on transmissibility using regression-based methods. Further, it will be possible to adopt a genome-wide approach to identify loci in the bacteria that are associated with or under evolutionary selective pressure from a transmissibility phenotype. Loci identified as being associated with transmissibility will be validated using sequence data from other populations.</gtr:technicalSummary><gtr:potentialImpactText>The economy 
Advances in sequencing technology now allow the genomic characterization of M.tuberculosis (the cause of tuberculosis (TB)) on an unprecedented scale, and have the potential to greatly accelerate research aimed at understanding the biology of the bacterium, its phylogeny and the epidemiology of the disease. The knowledge generated in the project and application of the research could ultimately benefit the pharmaceutical industry and those developing TB diagnostics and vaccines, as well as communities both in the UK and overseas exposed to the disease. Ultimately, through reduced occurrence of TB, the knowledge gained in this study could improve the health and wealth of the nation and globally. The methods used in this project could have application beyond TB, so help more widely in the control and prevention of infectious diseases in both humans and animals, with associated economic benefits. 

The general public
M.tuberculosis is a major cause of disease, killing ~2 million people globally each year, and drug resistant forms of TB and HIV are making control difficult. Genomics insights into transmission could lead ultimately to improved control measures adopted globally. The project therefore specifically addresses the MRC strategic aim to impact positively on global health, and to assist with bringing the health impacts of fundamental research to people more quickly. 

Academic and industrial organisations
New sequencing technologies have the ability to generate vast amounts of data, but there is a need to translate this information into knowledge useable by other research scientists and industry. Our work will provide tools useful for genomic data analysis and modeling, which can be utilized across infectious diseases and in different settings. An understanding of genomic variation underlying transmission could lead to laboratory experiments for M. tuberculosis pathogenesis and host interaction, improved tests for detecting transmissible M. tuberculosis, and insights for academics involved in policy formulation. Scientific developments arising would enhance the commercial private sector for the production of diagnostics, vaccines and other control measures. We have links with some of these companies (e.g. GSK) and where required will use licensing agreements through the LSHTM technology transfer office to ensure pipelines to vaccine or other translation tool production and exploitation are in place. Developing a basic understanding of the genomic pathways in this study will not only be important for understanding virulence and transmission mechanisms in M.tuberculosis, but has practical applications for other mycobacteria including M.bovis - the cause of TB in humans and cows. 
Any technology developed may have enormous implications for policy makers for future disease outbreaks and impact on exports.

Training opportunities
The proposal will employ and train and develop a scientist with diverse experience with an 'omic mentality that can be applied in academia, the public sector and industry. The multidisciplinary project team will add to the UK science base in an important and economically vital research area. The researchers working on the project will develop team working and project management skills, which they can apply in all employment sectors. Importantly, the scope for multidisciplinary interactions in this proposal should not be underestimated. The researcher employed to carry out the planned activities will have unique opportunities for engagement with experts (e.g. in the LSHTM TB Centre) in TB biology, biotechnology, clinical care, genomic epidemiology, and public health. Thus, our proposal will impact on the creation of human resources that could subsequently be employed in challenging interdisciplinary projects in industry, academia and government.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>355837</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Agency for Science, Technology and Research (A*STAR)</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:department>Genome Institute of Singapore</gtr:department><gtr:description>Sequencing - GIS</gtr:description><gtr:id>642B852D-D9D7-438C-9484-4079C8B5D547</gtr:id><gtr:impact>Sequence data, and scientific publications.</gtr:impact><gtr:outcomeId>58c72a88d92c64.02614054-1</gtr:outcomeId><gtr:partnerContribution>Sequencing data.</gtr:partnerContribution><gtr:piContribution>Samples for pacino sequencing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>All raw and processed sequence data across ~3000 Mycobacterium tuberculosis.</gtr:description><gtr:id>53CD7346-0EB5-431A-BC2C-66F027C41606</gtr:id><gtr:impact>Scientific publications.</gtr:impact><gtr:outcomeId>58c728c35c2436.93250550</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Karonga sequencing database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8EDAB8DE-E490-4C9D-8923-CD76F288A645</gtr:id><gtr:title>Turkish and Japanese Mycobacterium tuberculosis sublineages share a remote common ancestor.</gtr:title><gtr:parentPublicationTitle>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cd4d375519c6d237092943bc9bcb901"><gtr:id>1cd4d375519c6d237092943bc9bcb901</gtr:id><gtr:otherNames>Refr?gier G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1567-1348</gtr:issn><gtr:outcomeId>5a31e51fd9b6e6.63389144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAEAEC9E-38C4-473D-8DD0-8FA74E2FF7DC</gtr:id><gtr:title>Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78111465c3beac2f3fd2cd67ce83ebac"><gtr:id>78111465c3beac2f3fd2cd67ce83ebac</gtr:id><gtr:otherNames>Nakatani Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5aa707be4729a4.79922254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B619990-BC9B-4922-8FA1-46B803F1D552</gtr:id><gtr:title>Primary macrophages and J774 cells respond differently to infection with Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/203bd51f2201982d84cb5acd7333eeb4"><gtr:id>203bd51f2201982d84cb5acd7333eeb4</gtr:id><gtr:otherNames>Andreu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa707bfef75b4.46390702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E5DCAC8-5459-43CB-9BD5-08A0DD0D686F</gtr:id><gtr:title>The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05df376852e20acb4fc91c6703e4b664"><gtr:id>05df376852e20acb4fc91c6703e4b664</gtr:id><gtr:otherNames>Dheda K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5aa7085c86f4f9.13489677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E311A1E-D00C-400A-9EE1-A7DB753A0707</gtr:id><gtr:title>Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f9d2141b38d4ce9557dee7636535580"><gtr:id>1f9d2141b38d4ce9557dee7636535580</gtr:id><gtr:otherNames>Sengstake S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>5a6d8ffaf2a8d6.28881215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AE4F506-6E98-4202-8E3D-D06AFB58EAE4</gtr:id><gtr:title>Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05df376852e20acb4fc91c6703e4b664"><gtr:id>05df376852e20acb4fc91c6703e4b664</gtr:id><gtr:otherNames>Dheda K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5aa7085c45fd99.82070865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D5E1790-EC16-4650-A381-29603C3AF1DC</gtr:id><gtr:title>Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/379436f10e3e2eaecb37aa253b3e3a15"><gtr:id>379436f10e3e2eaecb37aa253b3e3a15</gtr:id><gtr:otherNames>Ravenhall M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>5a2fd938131016.13877320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A1EEF5D-9F1E-422D-B029-29D6524D8256</gtr:id><gtr:title>Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ba3a7d68cb58d8b1f7a949a40729d3d"><gtr:id>3ba3a7d68cb58d8b1f7a949a40729d3d</gtr:id><gtr:otherNames>Phelan JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>56d8d6269623a8.76590626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9797B82B-D51F-46A9-A5FD-596D346362C2</gtr:id><gtr:title>Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b3ad74b2cbfefa8a45e2a92ee2f8910"><gtr:id>2b3ad74b2cbfefa8a45e2a92ee2f8910</gtr:id><gtr:otherNames>Coll F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa707bea1e960.87345742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CED8EA01-211F-4DD9-8E02-E081214663AE</gtr:id><gtr:title>The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>5aa707c07bde96.67282383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>928AB984-81E2-4DBE-9388-2D6197E5352E</gtr:id><gtr:title>A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8cd28fb819e640500d91bbf01c1b070"><gtr:id>e8cd28fb819e640500d91bbf01c1b070</gtr:id><gtr:otherNames>Sheen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>5aa707bf5800b1.95321357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E7C64DF-056E-4EA3-9C37-0EABE9EAE1C4</gtr:id><gtr:title>Single nucleotide polymorphisms in efflux pumps genes in extensively drug resistant Mycobacterium tuberculosis isolates from Pakistan.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d0e3d97ed14e6e5316055b30c4e760"><gtr:id>35d0e3d97ed14e6e5316055b30c4e760</gtr:id><gtr:otherNames>Kanji A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>5aa707bf1d4649.21892833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4885E572-78A4-43C7-8451-80571C701446</gtr:id><gtr:title>Methylation in Mycobacterium tuberculosis is lineage specific with associated mutations present globally.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa707bee74241.31092087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F96F99D-466F-43E1-A3C7-9A1F7E11E1A8</gtr:id><gtr:title>Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>585d51a00ab225.48847567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6FC311E-47C2-42A9-8926-C3D482D690E9</gtr:id><gtr:title>Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>International journal of mycobacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d0e3d97ed14e6e5316055b30c4e760"><gtr:id>35d0e3d97ed14e6e5316055b30c4e760</gtr:id><gtr:otherNames>Kanji A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2212-5531</gtr:issn><gtr:outcomeId>5aa7085d127e87.87102095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C8BA8B5-BCF7-49F7-9C85-393CBCBE6F61</gtr:id><gtr:title>G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ee64bc72ee91a866c2a662eb162a35b"><gtr:id>2ee64bc72ee91a866c2a662eb162a35b</gtr:id><gtr:otherNames>Dombrowski JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>5a2fd371bbc9f5.46406497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>319C9F86-B8B3-40F4-AD47-F9F14C4A8243</gtr:id><gtr:title>Genomic variation in two gametocyte non-producing Plasmodium falciparum clonal lines.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74857d2b9bd60c065bebd0bd630bb80d"><gtr:id>74857d2b9bd60c065bebd0bd630bb80d</gtr:id><gtr:otherNames>Campino S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>585d5076dfc4a9.33232793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BB7F1CF-9D27-4977-90EC-78FEEDB9BBFC</gtr:id><gtr:title>Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action.</gtr:title><gtr:parentPublicationTitle>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7299b472f0fec84febfd64ee141c3e2"><gtr:id>d7299b472f0fec84febfd64ee141c3e2</gtr:id><gtr:otherNames>McNerney R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1201-9712</gtr:issn><gtr:outcomeId>5aa7085cca3ff2.91847554</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N010469/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>D640D1B8-B141-4DFC-BCD3-CEADD848A918</gtr:id><gtr:text>GCRF</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>